» Articles » PMID: 18523891

Mucoadhesive Microspheres for Gastroretentive Delivery of Acyclovir: in Vitro and in Vivo Evaluation

Overview
Journal AAPS J
Specialty Pharmacology
Date 2008 Jun 5
PMID 18523891
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present investigation was to evaluate the potential use of mucoadhesive microspheres for gastroretentive delivery of acyclovir. Chitosan, thiolated chitosan, Carbopol 71G and Methocel K15M were used as mucoadhesive polymers. Microsphere formulations were prepared using emulsion-chemical crosslinking technique and evaluated in vitro, ex-vivo and in-vivo. Gelatin capsules containing drug powder showed complete dissolution (90.5 +/- 3.6%) in 1 h. The release of drug was prolonged to 12 h (78.8 +/- 3.9) when incorporated into mucoadhesive microspheres. The poor bioavailability of acyclovir is attributed to short retention of its dosage form at the absorption sites (in upper gastrointestinal tract to duodenum and jejunum). The results of mucoadhesion study showed better retention of thiolated chitosan microspheres (8.0 +/- 0.8 h) in duodenal and jejunum regions of intestine. The results of qualitative and quantitative GI distribution study also showed significant higher retention of mucoadhesive microspheres in upper GI tract. Pharmacokinetic study revealed that administration of mucoadhesive microspheres could maintain measurable plasma concentration of acyclovir through 24 h, as compared to 5 h after its administration in solution form. Thiolated chitosan microsphere showed superiority over the other formulations as observed with nearly 4.0-fold higher AUC(0-24) value (1,090 +/- 51 ng h/ml) in comparison to drug solution (281 +/- 28 ng h/ml). Overall, the result indicated prolonged delivery with significant improvement in oral bioavailability of acyclovir from mucoadhesive microspheres due to enhanced retention in the upper GI tract.

Citing Articles

Evaluation of Ulcer Protective Activity of L. Extract-Loaded Chitosan Microspheres in Ethanol-Induced Ulcer in Rat Model.

Garg S, Singla R, Rahman M, Sharma R, Mittal V Evid Based Complement Alternat Med. 2022; 2022:4907585.

PMID: 36212972 PMC: 9546716. DOI: 10.1155/2022/4907585.


Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems.

Subramanian D, Langer R, Traverso G J Nanobiotechnology. 2022; 20(1):362.

PMID: 35933341 PMC: 9356434. DOI: 10.1186/s12951-022-01539-x.


Chitosan and Sodium Alginate Implementation as Pharmaceutical Excipients in Multiple-Unit Particulate Systems.

cierna M, Mucaji P, Spaglova M, cuchorova M, Macho O Polymers (Basel). 2022; 14(14).

PMID: 35890597 PMC: 9316923. DOI: 10.3390/polym14142822.


Surveying the Oral Drug Delivery Avenues of Novel Chitosan Derivatives.

Sivanesan I, Tasneem S, Hasan N, Shin J, Muthu M, Gopal J Polymers (Basel). 2022; 14(11).

PMID: 35683804 PMC: 9182633. DOI: 10.3390/polym14112131.


Injectable microfluidic hydrogel microspheres based on chitosan and poly(ethylene glycol) diacrylate (PEGDA) as chondrocyte carriers.

Lin L, Wang Y, Wang L, Pan J, Xu Y, Li S RSC Adv. 2022; 10(65):39662-39672.

PMID: 35515410 PMC: 9057443. DOI: 10.1039/d0ra07318k.


References
1.
Bernkop-Schnurch A, Guggi D, Pinter Y . Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J Control Release. 2003; 94(1):177-86. DOI: 10.1016/j.jconrel.2003.10.005. View

2.
Rossi S, Sandri G, Ferrari F, Bonferoni M, Caramella C . Buccal delivery of acyclovir from films based on chitosan and polyacrylic acid. Pharm Dev Technol. 2003; 8(2):199-208. DOI: 10.1081/pdt-120018490. View

3.
OBrien J . Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989; 37(3):233-309. DOI: 10.2165/00003495-198937030-00002. View

4.
Jain S, Jain R, Chourasia M, Jain A, Chalasani K, Soni V . Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech. 2005; 6(1):E35-41. PMC: 2750409. DOI: 10.1208/pt060108. View

5.
RUHNEK-FORSBECK M, Sandstrom E, Andersson B, Eriksson G, HERSLE K, Lovhagen G . Treatment of recurrent genital herpes simplex infections with oral acyclovir. J Antimicrob Chemother. 1985; 16(5):621-8. DOI: 10.1093/jac/16.5.621. View